Idorsia reacquires the world-wide rights to aprocitentan
September 06, 2023 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Aprocitentan, Idorsia’s oral, dual endothelin receptor antagonist is currently under review with health authorities for the treatment of patients with...
Idorsia reacquires the world-wide rights to aprocitentan
September 06, 2023 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Aprocitentan, Idorsia’s oral, dual endothelin receptor antagonist is currently under review with health authorities for the treatment of patients with...
Idorsia gibt Finanzergebnisse für das erste Halbjahr 2023 bekannt – Anpassung des Unternehmens zur Schaffung von nachhaltigem Wert
July 25, 2023 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Ad-hoc-Mitteilung gemäss Art. 53 KR Allschwil, Schweiz – 25. Juli 2023 Idorsia Ltd (SIX: IDIA) gab heute die Finanzergebnisse für das erste Halbjahr 2023 bekannt. Business Highlights Transaktion...
Idorsia announces financial results for the first half 2023 – adapting the company to create sustainable value
July 25, 2023 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – July 25, 2023 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first half of 2023. Business highlights...
Idorsia kündigt eine Kostensenkungsinitiative an, die bis Ende 2023 umgesetzt werden soll
July 21, 2023 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Ad-hoc-Mitteilung gemäss Art. 53 KR Um Idorsia die nötige Zeit zu geben, um kommerzielle Erfolge zu erzielen, müssen alle Mittel, die beschafft werden, vorrangig für Aktivitäten verwendet werden, die...
Idorsia announces a cost reduction initiative to be implemented by the end of 2023
July 21, 2023 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR In order to give Idorsia the necessary time to realize commercial success – any funds that are raised must be prioritized on activities to maximize their...
Idorsia sells its Asia Pacific (ex-China) operations – including select license rights to products – to Sosei Heptares for a total consideration of CHF 400 million
July 20, 2023 02:30 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LRAllschwil, Switzerland – July 20, 2023Idorsia Ltd (SIX: IDIA) today announced the sale of its operating businesses in the Asia Pacific (ex-China) region...
Idorsia sells its Asia Pacific (ex-China) operations – including select license rights to products – to Sosei Heptares for a total consideration of CHF 400 million
July 20, 2023 02:30 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LRAllschwil, Switzerland – July 20, 2023Idorsia Ltd (SIX: IDIA) today announced the sale of its operating businesses in the Asia Pacific (ex-China) region...
Idorsia announces its insomnia medication, QUVIVIQ (daridorexant), is now covered by CVS
July 10, 2023 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LRThe approximately 20 million US lives covered by CVS will now have easier and more affordable access to QUVIVIQAllschwil, Switzerland & Radnor, PA, United...
Idorsia announces its insomnia medication, QUVIVIQ (daridorexant), is now covered by CVS
July 10, 2023 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LRThe approximately 20 million US lives covered by CVS will now have easier and more affordable access to QUVIVIQAllschwil, Switzerland & Radnor, PA, United...